OKX Launches in France, With 'Mild Mild West' Screening in Cannes
French users now have access to deep liquidity spot trading, staking, trading bots, and more than 270 cryptocurrencies, including 60+ crypto-Euro pairs, within a secure, transparent, and compliant framework. The OKX platform includes standout features such as crypto earn products, automated trading bots, and a roadmap of localized offerings designed for the French market. Combining a strong focus on regulation and customer experience, OKX brings powerful infrastructure with fully localized customer support.
'Launching our MiCA-compliant platform in France is a major milestone in our European expansion,' said Erald Ghoos, CEO of OKX Europe. 'France is a key market for us, and we're proud to offer a fully regulated, localized experience with seamless Euro access, low fees, and deep liquidity. We're committed to building trust through compliance, transparency, and world-class service tailored to the French crypto community.'
To mark the launch, OKX hosted an exclusive red carpet event in Cannes featuring a screening of its film 'Mild Mild West,' which challenges outdated stereotypes of crypto as the 'wild west' and highlighting the industry's evolution toward regulation and trust, starring Vincent Cassel, Chazz Palminteri and Bonnie Chen.
The launch in France follows a year of significant global momentum for OKX. Over the past 12 months, the company has seen a double-digit percentage increase in active users, a substantial rise in assets under management (AUM), and a more than 30% growth in workforce across the EEA. OKX continues to build out its presence in Europe with a firm focus on regulatory compliance, innovation, and user protection.
OKX is MiCA-compliant and was among the first global exchanges to meet this new regulatory standard, and has now started passporting its products and services via its license from Malta. Over the last few weeks, OKX hosted exclusive launch events in Berlin – Germany, Warsaw – Poland, and Madrid – Spain, to officially announce its fully localized platform in the markets. Last year, OKX also launched in the Netherlands and Belgium.
The company also publishes monthly Proof of Reserves, leading the industry in transparency and user protection. With 31 consecutive monthly snapshots, OKX continues to raise the bar for industry reporting standards.
Learn more at okx.com
About OKXTrusted by more than 60 million customers around the globe, OKX is a technology company building a decentralized future that makes the world more tradable, transparent and connected. We're known for being one of the fastest and most reliable crypto apps in the world, and have processed trillions of dollars in transactions.
We have key regional offices, including headquarters in San José, California, for the Americas and in Dubai for the Middle East. We also have offices in New York, Hong Kong, Singapore, the Republic of Türkiye, Australia and Europe. Over the past several years, we've built one of the world's most comprehensive regulatory compliant, licensed crypto companies. We hold licenses in the United States, the UAE, EEA, Singapore and Australia, as well as in other markets.
We're steadfastly committed to transparency and security and publish Proof of Reserves reports on a monthly basis. To learn more about OKX, download our app or visit: okx.com.
Disclaimer
Logo – https://mma.prnewswire.com/media/2014295/OKX_Logo_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/okx-launches-in-france-with-mild-mild-west-screening-in-cannes-302495522.html
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
25 minutes ago
- Malaysian Reserve
Neurizon Enters into Global License with Elanco to Accelerate Commercialisation of NUZ-001
Highlights: Neurizon® Therapeutics and Elanco Animal Health enter into an exclusive global licensing agreement Provides worldwide rights for Neurizon to utilise Elanco's intellectual property, providing exclusive access to an extensive package of non-clinical studies and manufacturing data and outlines key terms for a future supply agreement for GMP-compliant Monepantel Provides a clear pathway for accelerated global commercialisation of NUZ-001[1] and significantly de-risks future global regulatory approval processes The license agreement represents the first step in formalising Neurizon's relationship with Elanco, with the next step focused on finalising a supply agreement expected H2 CY 2025 MELBOURNE, Australia, July 2, 2025 /PRNewswire/ — Neurizon Therapeutics Limited (ASX: NUZ & NUZOA) ('Neurizon' or 'the Company'), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce it has executed an exclusive global license agreement with Elanco Animal Health Incorporated (Elanco; NYSE: ELAN) and affiliates for Monepantel, the active pharmaceutical ingredient in NUZ-001, Neurizon's lead investigational therapy in development for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases in humans. This license agreement represents a critical inflection point for Neurizon, further strengthening the Company's strategic outlook for the development, manufacturing and potential future commercialisation of NUZ-001. It also significantly supports the Company's regulatory foundations, providing ongoing access to critical animal safety data and manufacturing data, key pillars required to support future clinical trials, potential regulatory approvals and global market entry. Dr. Michael Thurn, Managing Director and Chief Executive Officer, commented: 'This license agreement with Elanco marks a watershed moment in Neurizon's journey to become a leader in the accelerated development of treatments for neurodegenerative diseases. This strategic milestone provides exclusive access to a comprehensive package of non-clinical studies and manufacturing data, dramatically reducing near-term development costs and accelerating development timelines. All of this is in exchange for a nominal up-front payment, small back-ended regulatory approval and commercial sale milestones and single-digit royalty payments on future global net sales. Neurizon is now well-positioned to accelerate the path to market and advance new treatment options for people affected by devastating neurodegenerative diseases.' Mr. Sergio Duchini, Non-Executive Chairman, commented: 'On behalf of the Board, I am pleased to endorse this landmark agreement with Elanco, which represents a strategically significant step forward for Neurizon. This agreement not only strengthens our clinical and regulatory position but also reflects our strong commitment to accelerating the development of meaningful therapies for people living with neurodegenerative diseases. We are also very happy to be making this important step in formalising our relationship with Elanco and look forward to building on this foundation as we progress towards finalising a supply agreement later this year.' Key Terms of the Licensing Agreement: Exclusive Global Rights: Neurizon is granted exclusive global rights to Elanco's data package and related intellectual property for monepantel to develop and commercialise NUZ-001 and its related compounds for the treatment, palliation, prevention, or cure of neurodegenerative diseases in humans. Upfront Payment: A nominal upfront licensing fee is payable to Elanco upon execution of the agreement[2]. Milestone Payments: Total Development milestone payments for the initial and subsequent licensed products, indications, or presentations of US$9.75 million and US$5.2 million, respectively. Elanco will also be eligible for milestone payments of up to US $65 million based on sales milestones[3]. Royalties: Elanco will receive tiered single-digit royalties on global net sales of licensed products. Supply: The agreement outlines certain key terms, including duration and price, for the conclusion of a Supply Agreement. Supply Agreement Neurizon and Elanco remain focused on finalising a supply agreement, with a follow-up announcement anticipated in H2 CY 2025. This next phase of the collaboration is expected to provide Neurizon with long-term, scalable source of GMP-compliant monepantel to support ongoing clinical development, regulatory submissions, and future global commercialisation of NUZ-001. -ENDS- This announcement has been authorized for release by the Board of Neurizon Therapeutics Limited. About Neurizon Therapeutics Limited Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease. Neurizon's strategy is to accelerate access to effective ALS treatments for patients while exploring NUZ-001's potential for broader neurodegenerative applications. Through international collaborations and rigorous clinical programs, Neurizon is dedicated to creating new horizons for patients and families impacted by complex neural disorders. Neurizon® is a registered trademark of Neurizon Therapeutics Limited [1] NUZ-001 is Neurizon Therapeutics formulation of monepantel for use in neurodegeneration applications. [2] The amount is not material to Neurizon's current cash position [3] If triggered, the sales milestone payments will not fall due until six months after the first commercial sale. The remaining regulatory and commercial milestone payments will become due 30 days after the relevant milestone is met.
Malaysian Reserve
an hour ago
- Malaysian Reserve
AAPL INVESTOR NOTICE: Apple Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
SAN DIEGO, July 2, 2025 /PRNewswire/ — Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Apple Inc. (NASDAQ: AAPL) securities between June 10, 2024 and June 9, 2025, all dates inclusive (the 'Class Period'), have until August 19, 2025 to seek appointment as lead plaintiff of the Apple class action lawsuit. Captioned Tucker v. Apple Inc., No. 25-cv-05197 (N.D. Cal.), the Apple class action lawsuit charges Apple as well as certain of Apple's top current and former executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the Apple class action lawsuit, please provide your information here: You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at info@ CASE ALLEGATIONS: The Apple class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) Apple misstated the time it would take to integrate the advanced artificial intelligence ('AI')-based Siri features into its devices; (ii) accordingly, it was highly unlikely that these features would be available for the iPhone 16; (iii) the lack of such advanced AI-based features would hurt iPhone 16 sales; and (iv) as a result, Apple's business and/or financial prospects were overstated. The Apple class action lawsuit further alleges that on March 7, 2025, Apple announced it was indefinitely delaying promised updates to its Siri digital assistant. The Apple class action lawsuit alleges that on this news, the price of Apple stock fell. Then, on March 12, 2025, the Apple class action lawsuit further alleges that Morgan Stanley published a report in which analyst Erik Woodring lowered his price target on Apple from $275 to $252, asserting that the delay in introducing advanced Siri features would impact iPhone upgrade cycles throughout 2025 and 2026, and presenting evidence that roughly 50% of iPhone owners who did not upgrade to the iPhone 16 attributed their decision to such delays. On this news, the price of Apple stock fell further, according to the complaint. Thereafter, the Apple class action lawsuit alleges that on April 3, 2025, the Wall Street Journal published an article titled 'Apple and Amazon Promised Us Revolutionary AI. We're Still Waiting,' which stated, in relevant part, that '[w]ith 'more personal' Siri . . . , the tech giant[] marketed features [it] ha[s] yet to deliver,' and suggested that while 'this is challenging technology and the cost of getting it wrong is devastatingly high, especially for [a] compan[y] like Apple . . . that must build trust with customers,' 'the same responsibility applies to marketing: They shouldn't announce products until they're sure they can deliver them.' On this news, the price of Apple stock fell more than 7%, according to the complaint. Finally, on June 9, 2025, Apple hosted its Worldwide Developer Conference ('WWDC'), almost one year to the day after first announcing the suite of supposedly forthcoming Apple Intelligence features at the 2024 WWDC, and Apple failed to announce any new updates regarding advanced Siri features, according to the complaint. On this news, the price of Apple stock fell further, according to the complaint. Last year, Robbins Geller secured a $490 million recovery in a securities fraud class action case alleging Apple CEO Timothy Cook made false and misleading statements to investors – the third-largest securities class action recovery ever in the Northern District of California and the fifth-largest such recovery ever in the Ninth Circuit. In the order granting final approval of the settlement, the court recognized the 'skill and strategic vision, as well as the risk taken by [Robbins Geller]' in securing the sizeable recovery while efficiently managing the 'uniquely complex' aspects of the case against 'highly sophisticated and experienced counsel and defendants.' Learn more by clicking here. THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Apple securities during the Class Period to seek appointment as lead plaintiff in the Apple class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Apple class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Apple class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Apple class action lawsuit. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information: Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. Contact: Robbins Geller Rudman & Dowd LLP J.C. Sanchez, Jennifer N. Caringal 655 W. Broadway, Suite 1900, San Diego, CA 92101 800-449-4900 info@
Malaysian Reserve
3 hours ago
- Malaysian Reserve
Mondetta Clothing announces the appointment of Georgi Gvakharia as Vice President of Retail
WINNIPEG, MB, July 2, 2025 /CNW/ – Mondetta Clothing, a leading fashion company known for its active lifestyle label, Mondetta Performance Gear, performance-infused luxury apparel, Modern Ambition, Mondetta casual sportswear, and Mondetta Originals globally themed clothing today announced the appointment of Georgi Gvakharia as Vice President of Retail. In this role, a first for the company, Gvakharia will oversee retail operations across all of the organization's brands. Initially, he will lead the way as the company's Modern Ambition division makes its first foray into brick-and-mortar retail operations. 'We're excited to have Georgi join the team and look forward to how his expertise will help us grow the retail side of our business for all of our brands,' said Ash Modha, CEO and Co-Founder of Mondetta Clothing. 'His experience with prestige brands especially aligns with where we want the Modern Ambition brand to go, and we're delighted to have him join us on this journey.' Georgi brings a wealth of experience in luxury retail, having successfully launched and expanded high-end operations across North America. His leadership roles at renowned brands have equipped him with a deep understanding of market dynamics and consumer preferences. At Ralph Lauren, his focus on enhancing the customer experience has contributed to increased brand loyalty and sales growth. His strategic initiatives in the Canadian market demonstrate his ability to adapt and thrive in diverse retail landscapes. With a strong commitment to excellence, Georgi is well-positioned to continue driving success in high-end retail operations. 'I'm thrilled to join Mondetta at such a pivotal moment in its growth. The opportunity to shape the brand's retail journey, rooted in purpose, performance, and style, is both inspiring and deeply aligned with my values. Starting with Modern Ambition, I look forward to working alongside this exceptional team to build something truly meaningful in the luxury menswear space,' said Gvakharia. About Mondetta Clothing: Mondetta Clothing Inc. is a Canadian leisure and sportswear design and manufacturing company best known for its world flag-themed apparel. Based in Winnipeg, Manitoba, the company has four main divisions: Mondetta, Mondetta Originals, MPG, and Modern Ambition. Founded in 1986, Mondetta—a name that combines the French word 'monde' (world) with the Latin suffix 'etta' (small)—reflected the idea of a shrinking global village made possible by the rapid advancement of communications technologies. Since its inception, Mondetta has become a worldwide leader in sustainable, technical, lifestyle and activewear apparel.
